


In re application of  
Downes et al.  
Application No.: 10/658,115  
Page 2

Atty. Dkt. No. SALK3130-1 (088802-9702)

Amendments to the Claims/Listing of Claims

Please amend claims 1 and 10, and cancel claims 33-35 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound having the structure:



wherein:

A is a C3 up to C8 branched chain alkyl or substituted alkyl group, a C3 up to C7 cycloalkyl or substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl,

X is -C(O)- or -CH<sub>2</sub>-,


R is methyl or ethyl,

R<sup>1</sup> is H, hydroxy, alkoxy, benzyloxy, mesityloxy, or -OCH<sub>2</sub>C(O)OC<sub>2</sub>H<sub>5</sub>,

R<sup>2</sup> is H or R<sup>2</sup> can cooperate with R<sup>3</sup> to form a benzopyran, wherein the pyran ring has the structure:

In re application of  
 Downes et al.  
 Application No.: 10/658,115  
 Page 3

Atty. Dkt. No. SALK3130-1 (088802-9702)



wherein:

$R^6$  is not present if the pyran ring is unsaturated, or, if present, is selected from H, -OR, wherein R is alkyl or acyl, or  $R^6$  can cooperate with  $R^7$  to form a cyclic acetal, a cyclic ketal, or a cyclopropyl moiety, and

only one of  $R^7$  and  $R^8$  is present if the pyran ring is unsaturated, or  $R^7$  and  $R^8$  are independently H, carboxyl, cyano, hydroxy, alkoxy, thioalkyl, aryl, or  $R^7$  and  $R^8$  taken together comprise a carbonyl oxygen or an oxime nitrogen, or either  $R^7$  or  $R^8$  can cooperate with  $R^6$  to form a cyclic acetal, a cyclic ketal, or a cyclopropyl moiety,

$R^3$  can cooperate with  $R^2$  to form a benzopyran having the structure set forth above, or  $R^3$  is alkenyl or  $-\text{CH}=\text{CH}-\text{C}(\text{O})-\text{O}-\text{tBu}$ , optionally substituted aryl or heteroaryl, or optionally substituted arylalkenyl or heteroarylalkenyl,

$R^4$  is H or hydroxy, and

$R^5$  is H, hydroxy, alkoxy or aryloxy.

2. (Original) The compound of claim 1 wherein  $R^2$  and  $R^3$  cooperate to form a benzopyran.

DLMR\_278693.1

In re application of  
Downes et al.

Atty. Dkt. No. SALK3130-1 (088802-9702)

Application No.: 10/658,115  
Page 4

3. (Original) The compound of claim 2 wherein A is cyclopropyl, X is -C(O)-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> are absent, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

4. (Original) The compound of claim 2 wherein A is cyclopropyl, X is -CH<sub>2</sub>-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> are absent, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

5. (Original) The compound of claim 2 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> are absent, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

6. (Original) The compound of claim 2 wherein A is phenyl, X is -C(O)-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> are absent, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

7. (Original) The compound of claim 2 wherein A is phenyl, X is -C(O)-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> cooperate to form a dichlorocyclopropyl ring, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

8. (Original) The compound of claim 2 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> is methoxy, R<sup>6</sup> and R<sup>7</sup> cooperate to form a dichlorocyclopropyl ring, and R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are hydrogen.

9. (Original) The compound of claim 1 wherein R<sup>3</sup> is alkenyl.

10. (Currently Amended) The compound of claim [[9]] 1 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-C(O)-O-tBu.

11. (Original) The compound of claim 1 wherein R<sup>3</sup> is optionally substituted aryl or heteroaryl.

12. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is phenyl.

DLMR\_278693.1

In re application of  
Downes et al.

Atty. Dkt. No. SALK3130-1 (088802-9702)

Application No.: 10/658,115  
Page 5

13. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is p-thiomethyl-phenyl.

14. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is m-methoxy-phenyl.

15. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is m-acetyl-phenyl.

16. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 5-methyl-2-thiophene-yl.

17. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 5-acetyl-2-thiophene-yl.

18. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 4-dimethylamino-phenyl.

19. (Original) The compound of claim 11 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 4-dimethylamino-phenyl.

20. (Original) The compound of claim 11 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 2,3-(O-CH<sub>2</sub>-O)-phenyl.

21. (Original) The compound of claim 11 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is 2,3-(O-CH<sub>2</sub>-O)-phenyl.

22. (Original) The compound of claim 1 wherein R<sup>3</sup> is or optionally substituted arylalkenyl or heteroarylalkenyl.

In re application of  
Downes et al.

Atty. Dkt. No. SALK3130-1 (088802-9702)

Application No.: 10/658,115  
Page 6

23. (Original) The compound of claim 22 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-phenyl.

24. (Original) The compound of claim 22 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-phenyl.

25. (Original) The compound of claim 22 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-p-methoxy-phenyl.

26. (Original) The compound of claim 22 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-o-fluoro-phenyl.

27. (Original) The compound of claim 22 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-o-fluoro-phenyl.

28. (Original) The compound of claim 22 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-m-fluoro-phenyl.

29. (Original) The compound of claim 22 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-m-fluoro-phenyl.

30. (Original) The compound of claim 22 wherein A is cyclohexyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-p-fluoro-phenyl.

31. (Original) The compound of claim 22 wherein A is isopropyl, X is -C(O)-, R<sup>1</sup> R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen, and R<sup>3</sup> is -CH=CH-p-fluoro-phenyl.

32. (Original) A formulation comprising at least one compound according to claim 1 in a pharmaceutically acceptable carrier therefor.

DLMR\_278693.1

In re application of  
Downes et al.  
Application No.: 10/658,115  
Page 7

Atty. Dkt. No. SALK3130-1 (088802-9702)

33. - 35. (Cancelled)

36. (Original) A method for the treatment of hypercholesterolemia, said method comprising administering an effective amount of at least one compound according to claim 1 to a subject in need thereof.

37. (Original) A method for the treatment of cholestasis, said method comprising administering an effective amount of at least one compound according to claim 1 to a subject in need thereof.

DLMR\_278693.1